Immutep Ltd · ASX:IMM
Immutep — Prima BioMed — Q3 FY2014 Earnings Presentation
9 slides from Immutep's earnings presentation, May 6, 2014
Slide 1: 3rd quarter results for FY 2014 (period ended 31 March 2014)
3rd quarter results for FY 2014 (period ended 31 March 2014) Supplemental information to management discussion May 6, 2014 ASX:PRR; NASDAQ:PBMD; ISIN:US74154B2034
Slide 2: Important Notice
Important Notice The purpose of the presentation is to provide an update of the business of Prima BioMed Ltd ACN 009 237 889 (ASX:PRR; NASDAQ:PBMD; Deutsche Börse: YP1B.F). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and
Slide 3: CVac CAN-003: ASCO presentation
CVac™ CAN-003: ASCO presentation CAN-003 final PFS data accepted for oral presentation at ASCO Dr. Heidi Gray presenting author Abstract #5504, May 31st at 2:27pm Chicago local time Abstracts are made public at http://abstracts.asco.org/ on May 14th at 5:00pm US eastern time
Slide 4: CAN-003 data in 2014
CAN-003 data in 2014 Final data expected to be published in a medical journal PFS data also to be presented by Dr. Gray at WAGO meeting held from June 25-28 OS data expected to be mature for analysis in 4Q of CY 2014
Slide 5: Recent Updates to Clinical Advisory Board
Recent Updates to Clinical Advisory Board Eric Pujade-Lauraine, MD, PhD Established the French GINECO Group, head of the Women Cancers and Clinical research Department at Hôpitaux Universitaires Paris Center, site Hôtel-Dieu Christian Marth, MD, PhD President and founder of the Austrian Association
Slide 6: CAN-004-B trial of CVac second remission ovarian cancer
CAN-004-B trial of CVac second remission ovarian cancer 1st patient enrolled in April 2014 210-patient, phase 2, randomized trial of CVac versus standard of care in platinum-sensitive epithelial ovarian cancer patients in second remission Primary endpoint: overall survival Progression-free survival
Slide 7: CAN-301 pilot pancreatic cancer trial
CAN-301 pilot pancreatic cancer trial 40 resected pancreatic cancer patients; single-arm pilot trial Coordinating Investigator selected: Florian Lordick in Germany 1st patients expected July 2014
Slide 8: CVac manufacturing developments
CVac manufacturing developments Extending MNC shipping times from 24 hours to 48 hours (possibly longer) Progress on surrogate potency QC assay Supports optimized, cost effective, and scalable manufacturing of CVac
Slide 9: Financial results for 3rd quarter FY 2014
Financial results for 3rd quarter FY 2014* Net operating cash outflow for the quarter: A$1.60 million Net operating cash outflow YTD for FY 2014: A$10.04 million Income received in Q3: A$1.98 million Cash & term deposits at end of quarter: A$26.74 million Projected loss for total FY 2014: A$13 milli